🔬🩸 Hematology Updates: CAR-T Milestones, Myeloma Breakthroughs, and Global Access Expansions
From MHRA approvals and Breakthrough Therapy designations to next-gen CAR-T developments and public health initiatives in India—this week’s hematology roundup delivers the most critical updates driving innovation in blood cancer and rare disorder care.
💡 Key Highlights This Week:
✅ Takeda’s Adzynma approved by MHRA—the UK’s first authorized therapy for congenital thrombotic thrombocytopenic purpura (cTTP)
🧬 CARsgen’s allogeneic CAR-T (CT0596) shows 60% CR/sCR and 80% MRD-negativity in early multiple myeloma data
🧪 Arcellx’s anito-cel hits a 97% overall response rate with 68% CR/sCR and no severe CRS or ICANS in RRMM
🧠 InnoCare’s Mesutoclax becomes first BCL2 inhibitor with Breakthrough Therapy Designation in China
🧊 Artiva’s AlloNK + Rituximab delivers 64% CR and 19.4+ month median DoR in B-cell NHL with outpatient potential
🧒 SELLAS doses first pediatric AML patient in Phase 2 trial for SLS009 (CDK9 inhibitor) targeting high-risk mutations
🧪 ADC Therapeutics halts ADCT-602, shifts focus to Zynlonta + Columvi combo with greater than 90 percent CR in DLBCL
📱 Tamil Nadu launches mobile hemophilia app as part of award-winning public health expansion
🧬 Gujarat announces sickle cell anemia Centre of Competence backed by ₹6 crore to serve tribal populations
💊 Generic eltrombopag launch expands access for ITP and aplastic anemia through Camber’s AB-rated alternative
🎯 Whether you’re following next-gen immunotherapies, pediatric AML developments, or expanding access to essential treatments—this update brings you the most actionable insights in hematology.
📢 Stay Ahead in Hematology Research!
✅ Like, share, and subscribe for weekly updates on blood cancers, cell therapies, and global clinical breakthroughs.
#Hematology #MultipleMyeloma #Leukemia #Lymphoma #CAR_T #cTTP #BCL2Inhibitor #ClinicalTrials #BloodDisorders #BiotechNews #PharmaInnovation #LucidQuest #HealthcareUpdates #SickleCell #DLBCL #CDK9 #Hemophilia